Aim immunotech announces availability of the me/cfs clinical trial of its drug ampligen for enrollment to covid-19 long haulers

Aim immunotech announces availability of the me/cfs clinical trial of its drug ampligen for enrollment to covid-19 ‘long haulers' institutional review board authorizes public notification for potential enrollment of subjects ocala, fl / accesswire / december 24, 2020 / aim immunotech inc. (nyse american:aim) announced today that the post-covid-19 "long hauler" portion of the active amp-511 expanded access program (eap) protocol received approval from the institutional review board (irb) for a public notification of potential patient enrollment. eligible patients enrolled in the trial receive treatment with aim's flagship pipeline drug ampligen.
AIM Ratings Summary
AIM Quant Ranking